Sign in
Taking people in United StatesNo phase

Studies a test for Barrett's esophagus and esophageal cancer in at-risk people

Observes EsoGuard test results and care for people screened for Barrett's esophagus.

Key facts

Who runs it
Lucid Diagnostics, Inc.
Where
Lake Forest, United StatesSee the site
Trial code
Registry title
Lucid Registry Study
Status
Recruiting
People taking part
8,000 people, planned
Started
11 Apr 2023
Expected to end
31 Dec 2027
Type of study
Observational
Treatments tested
  • EsoCheck®
  • EsoGuard®
Record updated
28 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people whose healthcare provider has decided to screen them for Barrett's esophagus or esophageal cancer because their risk is higher. Screening uses the EsoCheck cell sample and the EsoGuard test.

Sex
All sexes can join.
Disease stage
People not yet diagnosed with Barrett's esophagus or esophageal adenocarcinoma, who are being screened because of higher risk.

Main reasons for not taking part

  • Cannot give written informed consent
  • Outside the population allowed by the EsoCheck device Instructions For Use

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Individuals in whom a healthcare provider has made the independent clinical decision to screen for BE/EAC (based on assessment of elevated disease risk) using EsoGuard for analysis of cell samples collected with EsoCheck
  • Provided written informed consent for prospective registry participation/data collection

Who cannot take part

  • Inability to provide written informed consent
  • Subjects who fall outside the eligible population defined by the EsoCheck device Instructions For Use (IFU)

Where in United States

  • LUCID DXLake Forest, United StatesContact: Lucid Dx LabsTaking people

About the trial

What the trial wants to find out

This is a multicenter, prospective, observational study designed to capture a limited set of data consisting of diagnostic test results and clinical management information on subjects who undergo EC/EG to assess for the presence of BE/EAC. Once sufficient time has elapsed for EsoGuard results to be available, as well as for any subsequent clinical evaluation to have been performed (e.g., upper endoscopy and any initial therapeutic management), study staff will obtain the desired information and record it in an electronic data collection (EDC) system, pertaining to subject demographics, pertinent medical history, and risk factors for BE or EAC as well as (1) information about the EsoCheck cell collection procedure and patient tolerance, (2) EsoGuard test result; (3) initial clinical management including upper endoscopy, if performed, and diagnosis (as determined by the endoscopist and the pathologist assessing any biopsies taken.

Read full original descriptionShow less

For subjects endoscopically confirmed with intestinal metaplasia, dysplasia, or cancer, the registry will collect additional clinical management and/or a therapeutic procedure(s) performed and other mid- to long-term outcomes.

For subjects who are negative for BE/EAC via EsoGuard or negative for BE/EAC via EGD will be offered the option of longer-term follow-up in the form of intermittent wellness checks.

The time point for collecting such information shall be fluid, depending on the time course of care provided subsequent to the EsoGuard result being available. Subject participation duration is dependent on EsoGuard results, physician referral, EGD results (if referred) and participation in long-term follow-up. If EG results are negative and subject is not referred for an EGD, participation could last 1 month. If a subject is confirmed with BE/EAC, participation may continue beyond this minimum for an indefinite period, with no predetermined maximum duration.

Treatments tested

  • EsoCheck®
  • EsoGuard®

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Prospective, Open-Label Registry Study of the Utilization of EsoGuard, on Samples Collected Using EsoCheck, in an At-Risk Population Undergoing Standard of Care Screening for, and Management of, Previously Undiagnosed Barrett's Esophagus and/or Esophageal Adenocarcinoma
Plain-language title
Studies a test for Barrett's esophagus and esophageal cancer in at-risk peopleGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
28 September 2026